Receptor binding profiles and behavioral effects of psilocybin analogs
The FASEB Journal May 1, 2022 Grant C. Glatfelter, David R. Manke, Andrew R. Chadayne et al. 1 citation
4‐phosphorloxy‐ N,N ‐dimethyltryptamine (psilocybin) is a naturally occurring psychedelic compound that is being investigated in clinical studies in conjunction with psychotherapy for treatment of several psychiatric disorders. It is well established that 4‐hydroxy‐ N,N ‐dimethyltryptamine (psilocin) is the bioactive metabolite of psilocybin which mediates its in vivo psychedelic activity in...